As a supplement to our well-known quarterly Outlook report, Biomedtracker is pleased to present a longer-term look at some key late-stage drugs projected to hit the market in 2026. These drugs represent new drug classes, major changes to standards of care, and/or large market opportunities across the wide range of indications covered by Biomedtracker and Datamonitor Healthcare. 

This report will enable you to:

• Identify high-impact launches – Discover drugs that could achieve blockbuster potential, transform treatment landscapes, or launch in new therapeutic classes.
• Anticipate competitive shifts – Understand which therapies may change the standard of care and disrupt existing markets.
• Track key regulatory milestones – Follow critical catalysts, including PDUFA dates, pivotal trial readouts, and first approvals.
• Support strategic decisions – Leverage our expert insights to enhance portfolio planning, competitors monitoring, and drive informed planning.
• Access concise analyst insights – Benefit from clear, one-page summaries for each highlighted drug with therapy area, company details, likelihood of approval, and links to deeper analysis on BMT.

To view the full report, download the PDF at the top of this page. Additionally, an Excel list of relevant upcoming catalysts for these drugs can be downloaded under the support material. 

Like our report? Have any questions or feedback? Please let us know at askanalyst@sagientresearch.com. 

For our disclosures, please read the Biomedtracker Research Standards.